| ER+/PR+ | ER+/PR- | ER-/PR+ | ER-/PR- | ||||
---|---|---|---|---|---|---|---|---|
Characteristics | HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI |
Age at diagnosis, per 5 yearsa | 1.05 | 1.04–1.06 | 1.07 | 1.04–1.09 | 1.07 | 1.03–1.10 | 1.06 | 1.05–1.07 |
Diagnosis year, per yearb | 0.93 | 0.92–0.94 | 0.92 | 0.90–0.94 | 0.95 | 0.91–0.98 | 0.96 | 0.95–0.97 |
Tumor stagec | 2.33 | 2.20–2.46 | 2.29 | 2.09–2.51 | 2.55 | 2.19–2.96 | 2.06 | 1.94–2.18 |
Tumor size (cm)d | 1.27 | 1.24–1.30 | 1.29 | 1.24–1.34 | 1.33 | 1.25–1.41 | 1.22 | 1.20–1.25 |
Axillary lymph node statuse | 1.71 | 1.65–1.78 | 1.55 | 1.46–1.66 | 1.61 | 1.44–1.80 | 1.64 | 1.58–1.70 |
Tumor gradef | 1.62 | 1.55–1.70 | 1.49 | 1.36–1.63 | 1.72 | 1.46–2.03 | 1.24 | 1.16–1.32 |